DC-CIK细胞联合^(125)I粒子组织间植入治疗中晚期肝癌的临床研究

Clinical study of DC-CIK cells combined with ^(125)I particle interstitial implantation in treatment of middle and advanced hepatocellular carcinoma

目的探讨树突状细胞(DC)-细胞因子诱导的杀伤细胞(CIK)即DC-CIK细胞联合125I放射性粒子植入治疗中晚期肝癌的疗效。方法将2013年10月至2017年6月该院收治的80例中晚期肝癌患者动态随机分为联合组(A组)、^(125)I粒子组(B组)、DC-CIK组(C组)和对照组(D组),每组20例。A组行^(125)I粒子植入后即开始给予DC-CIK细胞治疗,B组仅给予粒子植入治疗,C组仅给予DC-CIK免疫细胞治疗,D组给予常规对症治疗。治疗结束后比较各组患者免疫功能、生活质量、生存率等。结果 A组患者治疗后CD3^+、CD4^+、CD16^+CD56^+、CD3^+CD56^+、CD4^+/CD8^+比值明显上升,CD8^+效应细胞比例有所下降,与治疗前及其他3组治疗后比较,差异均有统计学意义(P<0.05)。A组患者中生活质量改善者明显多于其他3组,3、6、12个月生存率均明显高于其他3组,差异均有统计学意义(P<0.05)。结论 DC-CIK细胞联合125I粒子植入治疗中晚期肝癌安全、有效,对提高患者免疫功能、改善生活质量、延长生存率、提高疗效均具有重要作用。

Objective To investigate the clinical effect of dendritic cells (DC)- cytokine induced killer (CIK) cells combined with 125 I radioactive seeds implantation in the treatment of middle and advanced hepatocellular cancer. Methods Eighty patients with middle and advanced hepatocellular carcinoma in the hospital from October 2013 to June 2017 were dynamically and randomly divided into the combined group(A), 125 I particle group(B),DC-CIK group(C) and control group(D),20 cases in each group.The group A was given DC-CIK cell therapy immediately after conducting 125 I particle implantation,the group B was given 125 I particle implantation only,the group C was given DC-CIK immunocyte therapy only and the group D conducted the routine symptomatic treatment.The immune function,quality of life and survival rate.after treatment were compared among various groups. Results The ratios of CD3^+,CD4^+,CD16^+CD56^+,CD3^+CD56^+,CD4^+/CD8^+ in the group A were increased significantly,and the ratio of CD8^+ effector cells was somewhat decreased,which was statistically significantly different from the other three groups ( P <0.05).The patients with living quality improvement in the group A were significantly more than those in the group B,the 3,6,12-month survival rates in the group A were significantly higher than those in the other three groups,the differences were statistically significant( P <0.05). Conclusion DC-CIK cells combined with 125 I particle implantation is safe and effective in the treatment of middle and advanced hepatocellular carcinoma and plays an important role in increasing the immune function,improving the quality of life,prolonging the survival rate and improving the therapeutic effect.